4577 — Daito Pharmaceutical Co Share Price
0.000.00%
Last trade - 00:00- ¥31bn
- ¥39bn
- ¥47bn
- 66
- 74
- 44
- 69
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 15 | ||
| PEG Ratio (f) | 0.8 | ||
| EPS Growth (f) | 23.01% | ||
| Dividend Yield (f) | 3.52% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.6 | ||
| Price to Tang. Book | 0.61 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.63 | ||
| EV to EBITDA | 5.69 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.24% | ||
| Return on Equity | 4.2% | ||
| Operating Margin | 5.33% | ||
Financial Summary
| Year End 31st May | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 44,991.4 | 48,714.99 | 43,464 | 45,101 | 46,895 | 49,000 | 51,000 | 2.66% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +9.37 | +4.19 | +8.28 | -27.77 | -7.48 | -52.71 | +40 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Daito Pharmaceutical Co., Ltd. is a Japan-based company mainly engaged in the pharmaceutical ingredients and formulation business, as well as healthy food. The pharmaceutical ingredients business is engaged in the manufacture, purchase, sale and entrusted manufacture business of pharmaceutical ingredients used as raw materials for pharmaceutical manufacture and formulation. The formulation business is engaged in the manufacture, purchase, sale and entrusted manufacture business of prescription pharmaceuticals and pharmaceuticals for general-use medicines.
Directors
- Yasunobu Ohtsuga PRE (62)
- Junichi Kikuta SMD (68)
- Mitsuo Hirono MEO
- Masuo Nomura MEO
- Masamichi Takimoto MEO
- Hisao Abe DHR
- Kazushige Hizume EXO
- Kenji Fujita EXO
- Masahiro Harai EXO
- Hiroshi Kawahara EXO
- Kiyotaka Kido EXO
- Norio Kishi EXO
- Hiroshi Kubota EXO
- Yutaka Kuwashima EXO
- Kazutaka Nose EXO
- Nobuya Oka EXO
- Tatsuo Shinohara EXO
- Hisao Takahashi EXO
- Daiki Takeda EXO
- Katsuya Tani EXO
- Akihiko Yamada EXO
- Atsushi Saino IND (44)
- Last Annual
- May 31st, 2024
- Last Interim
- February 28th, 2025
- Incorporated
- June 30th, 1942
- Public Since
- March 24th, 2010
- No. of Shareholders
- 2,937
- No. of Employees
- 1,070
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 15,144,963
- Address
- 326, Yoka-machi, TOYAMA-SHI, 939-8567
- Web
- https://www.daitonet.co.jp/
- Phone
- +81 764215665
- Auditors
- KPMG AZSA LLC
Upcoming Events for 4577
Daito Pharmaceutical Co Ltd Split For 4577.T - Ratio 2-1
Full Year 2025 Daito Pharmaceutical Co Ltd Earnings Release
Similar to 4577
ASKA Pharmaceutical Holdings Co
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
What is the Daito Pharmaceutical Co share price?
As of Today at 20:11 UTC, shares in Daito Pharmaceutical Co are trading at ¥2,042. This share price information is delayed by 15 minutes.
How has the Daito Pharmaceutical Co share price performed this year?
Shares in Daito Pharmaceutical Co last closed at ¥2,042 and the price had moved by -17.99% over the past 365 days. In terms of relative price strength the Daito Pharmaceutical Co share price has underperformed the Nikkei 225 Index by -13.58% over the past year.
What are the analyst and broker recommendations for Daito Pharmaceutical Co?
The overall consensus recommendation for Daito Pharmaceutical Co is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Daito Pharmaceutical Co dividend yield?
The Daito Pharmaceutical Co dividend yield is 3.18% based on the trailing twelve month period.
Does Daito Pharmaceutical Co pay a dividend?
Last year, Daito Pharmaceutical Co paid a total dividend of ¥65, and it currently has a trailing dividend yield of 3.18%.Looking ahead, shares in Daito Pharmaceutical Co are due to go ex-dividend on 2025-05-29 and the next dividend pay date is 2025-08-01.
When does Daito Pharmaceutical Co next pay dividends?
Daito Pharmaceutical Co are due to go ex-dividend on 2025-05-29 and the next dividend pay date is 2025-08-01. The historic dividend yield on Daito Pharmaceutical Co shares is currently 3.18%.
How do I buy Daito Pharmaceutical Co shares?
To buy shares in Daito Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Daito Pharmaceutical Co?
As of the previous close price of ¥2,042, shares in Daito Pharmaceutical Co had a market capitalisation of ¥31bn.
Where are Daito Pharmaceutical Co shares listed?
Here are the trading details for Daito Pharmaceutical Co:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4577
What kind of share is Daito Pharmaceutical Co?
Based on an overall assessment of its quality, value and momentum Daito Pharmaceutical Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Daito Pharmaceutical Co share price forecast for 2025?
The analyst consensus target price for shares in Daito Pharmaceutical Co is ¥1,962. That is 3.92% below the last closing price of ¥2,042.
Analysts covering Daito Pharmaceutical Co currently have a consensus Earnings Per Share (EPS) forecast of ¥100 for the next financial year.
Find out moreWhat is the trend in the Daito Pharmaceutical Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Daito Pharmaceutical Co. Over the past six months, its share price has outperformed the Nikkei 225 Index by +1.05%.
As of the last closing price of ¥2,042, shares in Daito Pharmaceutical Co were trading -6.26% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Daito Pharmaceutical Co PE Ratio?
The Daito Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is 15. The shares last closed at ¥2,042.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Daito Pharmaceutical Co?
Daito Pharmaceutical Co's management team is headed by:
- Yasunobu Ohtsuga - PRE
- Junichi Kikuta - SMD
- Mitsuo Hirono - MEO
- Masuo Nomura - MEO
- Masamichi Takimoto - MEO
- Hisao Abe - DHR
- Kazushige Hizume - EXO
- Kenji Fujita - EXO
- Masahiro Harai - EXO
- Hiroshi Kawahara - EXO
- Kiyotaka Kido - EXO
- Norio Kishi - EXO
- Hiroshi Kubota - EXO
- Yutaka Kuwashima - EXO
- Kazutaka Nose - EXO
- Nobuya Oka - EXO
- Tatsuo Shinohara - EXO
- Hisao Takahashi - EXO
- Daiki Takeda - EXO
- Katsuya Tani - EXO
- Akihiko Yamada - EXO
- Atsushi Saino - IND